ICER's Ambitious 2018 Review Agenda Takes On Groundbreaking Treatments

Institute for Clinical and Economic Review plans to evaluate the cost effectiveness of gene therapy, CAR-T drugs and tissue-agnostic cancer drugs, among other treatments, in 2018.